Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.44 |
| ▸ | BACE2 | Q9Y5Z0 | 8/20 | 0.40 |
| ▸ | CTSD | P07339 | 4/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL932097 | 0.88 | BACE1 (0.39) | BACE1KCNH2BACE2CTSDREN | |
| SCHEMBL3359611 | 0.87 | BACE1 (0.37) | BACE1KCNH2BACE2CTSD | |
| SCHEMBL3360850 | 0.86 | BACE1 (0.38) | BACE1KCNH2BACE2CTSD | |
| SCHEMBL3359122 | 0.85 | BACE1 (0.36) | BACE1KCNH2BACE2CTSD | |
| SCHEMBL3357857 | 0.84 | BACE1 (0.62) | BACE1KCNH2BACE2 | |
| SCHEMBL3360616 | 0.83 | BACE1 (0.49) | BACE1KCNH2BACE2CTSDREN | |
| SCHEMBL3359171 | 0.83 | BACE1 (0.51) | BACE1KCNH2BACE2CTSD | |
| SCHEMBL3358912 | 0.82 | BACE1 (0.36) | BACE1KCNH2BACE2CTSDREN | |
| SCHEMBL3769867 | 0.81 | BACE1 (0.49) | BACE1KCNH2BACE2CTSD | |
| SCHEMBL930773 | 0.81 | BACE1 (0.39) | BACE1KCNH2BACE2CTSDREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010056194-A1 | 5H-PYRROLO [ 3, 4-B] PYRIDIN DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010056194-A1 | 5H-PYRROLO [ 3, 4-B] PYRIDIN DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | disclosed |
| US-20100125081-A1 | NEW COMPOUNDS 574 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
| US-20100125081-A1 | NEW COMPOUNDS 574 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
| US-20100125081-A1 | NEW COMPOUNDS 574 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125081-A1 | NEW COMPOUNDS 574 | PSEN1, PSEN2, BACE1 | BACE1 3/4885KCNH2 4727/4885BACE2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.